ZBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.0M
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
1.0M
0
0
0
0
Operating Expenses
108.7M
+40.5%
77.3M
-67.5%
238.0M
+352.6%
52.6M
-4.7%
55.2M
R&D
92.9M
+53.7%
60.4M
-72.8%
222.4M
+464.4%
39.4M
-8.4%
43.0M
SG&A
15.7M
-6.9%
16.9M
+8.5%
15.6M
+18.3%
13.2M
+8.6%
12.1M
Operating Income
-107659000
-39.2%
-77350000
+67.5%
-237984000
-352.6%
-52580000
+4.7%
-55163000
EBITDA
-107655000
-39.2%
-77344000
+67.5%
-237974000
-352.7%
-52569000
+4.7%
-55151000
Net Income
-111456000
-37.6%
-80987000
+66.3%
-240442000
-366.9%
-51499000
+1.4%
-52223000
EPS (Basic)
$-1.77
-21.2%
$-1.46
+67.8%
$-4.53
-271.3%
$-1.22
+2.4%
$-1.25
EPS (Diluted)
$-1.77
-21.2%
$-1.46
+67.8%
$-4.53
-271.3%
$-1.22
+2.4%
$-1.25
Shares (Diluted)
63.1M
+13.5%
55.6M
+4.8%
53.1M
+25.9%
42.2M
+0.7%
41.9M
Zenas BioPharma (ZBIO) โ€” Financials